Health Care [ 10/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.
In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles.
The company is headquartered in Salt Lake City, Utah.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 11, 25 | -1.36 Decreased by -2.17 K% | -0.88 Decreased by -55.42% |
| Nov 5, 24 | -1.11 Decreased by -5.44 K% | -1.32 Increased by +16.11% |
| Aug 7, 24 | -1.06 Decreased by -265.52% | -1.49 Increased by +28.86% |
| May 8, 24 | -0.09 Increased by +40.00% | -0.08 Decreased by -12.50% |
| Mar 13, 24 | -0.06 Decreased by -500.00% | -0.07 Increased by +14.29% |
| Nov 7, 23 | -0.02 Increased by +88.24% | -0.09 Increased by +77.78% |
| Aug 14, 23 | -0.29 Decreased by -314.29% | -0.12 Decreased by -141.67% |
| May 12, 23 | -0.15 Increased by +28.57% | -0.14 Decreased by -7.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 91.00 K Decreased by -46.47% | -13.55 M Decreased by -33.19% | Decreased by -14.89 K% Decreased by -148.81% |
| Sep 30, 24 | 87.00 K Decreased by -19.44% | -7.99 M Decreased by -230.27% | Decreased by -9.18 K% Decreased by -309.99% |
| Jun 30, 24 | 91.00 K Decreased by -66.17% | -6.79 M Increased by +73.01% | Decreased by -7.46 K% Increased by +20.23% |
| Mar 31, 24 | 73.00 K Decreased by -31.78% | -11.08 M Increased by +20.14% | Decreased by -15.18 K% Decreased by -17.06% |
| Dec 31, 23 | 170.00 K Decreased by -27.35% | -10.17 M Decreased by -218.08% | Decreased by -5.98 K% Decreased by -262.54% |
| Sep 30, 23 | 108.00 K Decreased by -37.93% | -2.42 M Increased by +80.06% | Decreased by -2.24 K% Increased by +67.88% |
| Jun 30, 23 | 269.00 K Increased by +668.57% | -25.14 M Decreased by -454.54% | Decreased by -9.35 K% Increased by +27.85% |
| Mar 31, 23 | 107.00 K Increased by +256.67% | -13.87 M Increased by +1.48% | Decreased by -12.97 K% Increased by +72.38% |